Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Tweed

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
BMC Medicine|September 9, 2020
Treatment estimands in clinical trials of patients hospitalised for COVID-19: ensuring trials ask the right questionsBrennan C Kahan, Tim P Morris, Ian R White, et al.
NEJM Evidence|August 15, 2022
Improving clinical trial interpretation with ACCEPT analysesMichelle N Clements, Ian R White, Andrew J Copas, et al.
Clinical Trials (London, England)|July 19, 2022
Rethinking intercurrent events in defining estimands for tuberculosis trialsTra My Pham, Conor D Tweed, James R Carpenter, et al.
BMC Pulmonary Medicine|August 16, 2019
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV statusConor D Tweed, Angela M Crook, Rodney Dawson, et al.
The Lancet. Microbe|July 29, 2024
Bedaquiline: what might the future hold?Emily S Shaw, Neil G Stoker, Jessica L Potter, et al.
BMC Infectious Diseases|July 13, 2018
Toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor D Tweed, Angela M Crook, Evans I Amukoye, et al.
The Lancet. Respiratory Medicine|November 17, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trialConor D Tweed, Rodney Dawson, Divan A Burger, et al.
The New England Journal of Medicine|September 2, 2022
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant TuberculosisFrancesca Conradie, Tatevik R Bagdasaryan, Sergey Borisov, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 25, 2021
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TBC D Tweed, G H Wills, A M Crook, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
BMC Medicine|September 9, 2020
Treatment estimands in clinical trials of patients hospitalised for COVID-19: ensuring trials ask the right questionsBrennan C Kahan, Tim P Morris, Ian R White, et al.
NEJM Evidence|August 15, 2022
Improving clinical trial interpretation with ACCEPT analysesMichelle N Clements, Ian R White, Andrew J Copas, et al.
Clinical Trials (London, England)|July 19, 2022
Rethinking intercurrent events in defining estimands for tuberculosis trialsTra My Pham, Conor D Tweed, James R Carpenter, et al.
BMC Pulmonary Medicine|August 16, 2019
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV statusConor D Tweed, Angela M Crook, Rodney Dawson, et al.
The Lancet. Microbe|July 29, 2024
Bedaquiline: what might the future hold?Emily S Shaw, Neil G Stoker, Jessica L Potter, et al.
BMC Infectious Diseases|July 13, 2018
Toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor D Tweed, Angela M Crook, Evans I Amukoye, et al.
The Lancet. Respiratory Medicine|November 17, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trialConor D Tweed, Rodney Dawson, Divan A Burger, et al.
The New England Journal of Medicine|September 2, 2022
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant TuberculosisFrancesca Conradie, Tatevik R Bagdasaryan, Sergey Borisov, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 25, 2021
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TBC D Tweed, G H Wills, A M Crook, et al.
Pageof 6